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Background/Aims:  The nonspecific clinical presentation of acute hepatitis A (AHA) mandates the detection of 
anti-hepatitis A virus IgM antibodies (IgM anti-HAV) in the serum for obtaining a definitive diagnosis. However, IgM 
anti-HAV might not be present during the early phase of the disease. The aim of this study was to determine the optimal 
time for repeating the IgM anti-HAV test (HAV test) in AHA patients with a negative initial test. Methods: In total, 261 
patients hospitalized with AHA were enrolled for this retrospective study. AHA was diagnosed when the test for IgM 
anti-HAV was positive and the serum alanine aminotransferase (ALT) level was ≥400 IU/L. Repeat HAV test was 
conducted after 1-2 weeks if the initial HAV test was negative but AHA was still clinically suspected. Results: The results 
of the initial HAV test were negative in 28 (10.7%) patients. The intervals from symptom onset to the initial-HAV-test day 
and from the peak-ALT day to the initial-HAV-test day were significantly shorter in the negative-initial-HAV-test group, but 
on multivariate analysis only the latter was significantly associated with negative results for the initial HAV test (β=-0.978; 
odds ratio [95% confidence interval]=0.376 [0.189-0.747]; P=0.005). The HAV test was positive in all patients when it was 
performed at least 2 days after the peak-ALT day. Conclusions: The results of HAV tests were significantly associated 
with the interval from the peak-ALT day to the HAV-test day. The optimal time for repeating the HAV test in clinically 
suspicious AHA patients with a negative initial HAV test appears to be at least 2 days after the peak-ALT day. (Korean J 
Hepatol 2012;18:56-62)
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INTRODUCTION
Acute hepatitis A (AHA) is the most common cause of 
acute hepatitis in Korea.
1,2 It usually results in a self-limited 
episode of acute hepatitis without chronic infection or 
complication.
3 The overall prognosis of AHA is excellent; 
about 60% of patients completely recover within 2 months 
and almost every affected person recovers within 6 months.
3 
Diagnosis of AHA is usually made by the detection of 
anti-hepatitis A virus IgM antibodies (IgM anti-HAV) in 
serum. IgM anti-HAV test (HAV test) have high diagnostic 
sensitivity and specificity of more than 99%.
4 The test result 
usually becomes positive at the onset of symptoms
5 and 
usually remains positive for approximately 4 months 
thereafter.
6 However, IgM anti-HAV is not detected in some 
patients with AHA, especially during the early phase of 
AHA. Previous studies suggested that initial HAV test was 
negative in 6.4-6.7% of patients with AHA.
7,8 Hence, 
repeating HAV test after 1-2 weeks is usually recommended 
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Figure 1. Definition of the phase of AHA. Phase I is the period 
from the AHA-associated symptom-onset day to the peak-ALT day.
Phase II is the period from the peak-ALT day to the peak-bilirubin 
day. Phase III is the period after the peak-bilirubin day. ALT, 
alanine aminotransferase.
HAV test. Nevertheless, data to substantiate this recom-
mendation is scarce and studies validating this suggestion 
are lacking. Therefore, we performed this retrospective 
study to evaluate the optimal time for repeating HAV test in 




We retrospectively reviewed the medical records of all 
patients with AHA who had been admitted to the Korea 
University Anam Hospital between January 2001 and 
December 2009. Patients were hospitalized if they suffered 
from severe generalized weakness and/or poor oral intake. 
AHA was diagnosed when the patients were found to be 
positive for IgM anti-HAV and had a serum alanine amino-
transferase (ALT) level of ≥400 IU/L. HAV test was 
repeated 1-2 weeks after the initial HAV test when the initial 
test result was negative but AHA was still clinically 
suspected and no other cause of acute hepatitis could be 
documented.
Definitions
Day 0, defined as the day of acute hepatitis-associated 
symptom onset, was determined by thoroughly reviewing 
the patients’ history through medical records. Serum ALT 
and bilirubin (BIL) levels were repeated in each patient 
every 2-3 days until peak levels of all parameters were 
identified in all enrolled patients.
The course of AHA was classified into 3 periods as 
follows (Fig. 1):
9
1) Phase I was defined as the period from day 0 to the day 
when serum ALT levels peak (peak-ALT day). The serum 
levels of both ALT and BIL usually increase during this 
period.
2) Phase II was defined as the period from the peak-ALT 
day to the day when serum BIL levels peak (peak-BIL day). 
The serum ALT levels decrease but serum BIL levels 
continue to increase during this period.
3) Phase III was defined as the period after the peak-BIL 
day. The serum levels of both ALT and BIL decreased 
during this period, but have not recovered to below the upper 
limit of normal.
In patients who were admitted during the phase II, the 
admission day was assumed as the peak-ALT day, and in 
those who were admitted during the phase III, the admission 
day was assumed as both peak-ALT day and the peak-BIL 
day.
Statistical analysis
Statistical analyses were performed using the Statistical 
Package for the Social Sciences (SPSS version 13.0; SPSS 
Inc., Chicago, IL, USA). Data are represented as mean± 
standard deviation (SD), or percentage values. Mann-Whitney 
U-test and the chi-square test were used to compare continuous 
and categorical variables, respectively.
To identify the significantly associated factors with the 
result of the initial HAV test, univariate analysis for age, sex, 
HBs (hepatitis B surface) antigen, duration of hospitalization, 
durations to the first HAV-test day from the day 0 to the first 
HAV-test day, peak-ALT and BIL days, the course of AHA at 
the first HAV-test day, ALT and BIL levels on the first HAV- 
test day, and peak-ALT and BIL levels were performed. 
Then, multivariate logistic regression analysis was performed 




A total of 261 patients with AHA were hospitalized 
during the study period. The mean age was 31.2±7.0 years 58  The Korean Journal of Hepatology Vol. 18. No. 1, March 2012
Table 1. Baseline characteristics of all enrolled patients with AHA
All patients (n=261)
Age (yr) 31.2±7.0
Male (n, %) 158 (60.5)
Positive hepatitis B surface antigen (n, %) 8 (3.1)
Duration of hospitalization (day) 9.2±5.7
Interval from the day 0 to hospitalization day (day) 5.3±2.6
Interval from the day 0 to the first HAV-test day (day) 6.3±2.9
Interval from peak-ALT day to the first HAV-test day (day) 0.5±1.7
Interval from peak-BIL day to the first HAV-test day (day) -4.8±22.9
ALT level on the first HAV-test day (IU/L) 2985.4±1944.5
BIL level on the first HAV-test day (mg/dL) 4.5±3.2
Peak-ALT level (IU/L) 3442.2±2033.8
Peak-BIL level (mg/dL) 7.3±4.3
ALT level on the positive HAV-test day (IU/L) 2823.1±1903.4
BIL level on the positive HAV-test day (mg/dL) 4.9±3.2
AHA, acute hepatitis A; HAV, hepatitis A virus; ALT, alanine aminotransferase; BIL, bilirubin.
Figure 2. Timing of the initial HAV test. At the time of the initial HAV test, about half of the patients were in phase 
II, and none of the patients with negative initial HAV test were in phase III. The HAV test was repeated 6.5±2.3 days
(mean±SD) after the first test in these 28 patients, at which time 6 (21.4%) patients were in phase II and 22 (78.6%) 
were in phase III. HAV, hepatitis A virus.
and 158 patients (60.5%) were men (Table 1). Patients were 
hospitalized 5.3±2.6 days after day 0. Baseline serum ALT 
and BIL levels were 2962.4±1961.3 IU/L and 4.5±3.2 
mg/dL, respectively. When the patients were classified at 
baseline according to the course of AHA, 61 (23.4%) 
patients belonged to phase I, 126 (48.3%) to the phase II, and 
74 (28.4%) to phase III. Peak serum ALT and BIL levels 
were 3442.2±2033.8 IU/L and 7.3±4.3 mg/dL, respectively.
The initial HAV test during hospitalization was performed 
6.3±2.9 days after day 0. The test was done during phase I in 
41 (15.7%) patients, phase II in 125 (47.9%) patients, and 
phase III in 95 (36.4%) patients (Fig. 2). Serum ALT and 
BIL levels at the time of first HAV test were 2985.4±1944.5 
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Table 2. Comparison of clinical and biochemical characteristics according to the results of the first HAV test
Negative initial IgM 
anti-HAV (n=28)





Age (yr) 31.4±5.7 31.1±7.1 0.971
Male (n, %) 23 (82.1) 135 (57.9) 0.013 0.285
Positive hepatitis B surface antigen (n, %) 0 (0) 8 (3.4) 0.319
Duration of hospitalization (day) 8.6±2.7 9.2±5.9 0.914
Interval from the day 0 to the first HAV-test day (day) 3.9±2.2 6.6±2.9 <0.001 0.691
Interval from peak-ALT day to the first HAV-test day (day) -1.5±1.5 0.7±1.6 <0.001 0.005
Interval from peak-BIL day to the first HAV-test day (day) -5.4±2.8 -4.8±24.3 0.890
ALT level on the first HAV-test day (IU/L) 2586.8±2322.5 3033.3±1894.2 0.064 0.351
BIL level on the first HAV-test day (mg/dL) 2.3±1.7 4.8±3.2 <0.001 0.286
Peak ALT level (IU/L) 4061.4±2105.3 3367.8±2016.9 0.078 0.668
Peak BIL level (mg/dL) 6.5±3.4 7.4±4.4 0.355
*Mann-Whitney  U  test or chi-square test; 
†Binary logistic regression analysis.
HAV, hepatitis A virus; ALT, alanine aminotransferase; BIL, bilirubin.
Figure 3. Proportions of patients with negative initial HAV tests 
at each day from the peak-ALT day (defined as day 0). The 
proportion of patients with a negative initial HAV test decreased 
as the initial HAV test time approached the peak-ALT day, and 
the test for IgM anti-HAV was positive in all patients at 2 days
after the peak-ALT day.
HAV test was positive in 233 (89.3%) patients, thus being 
diagnosed as AHA, while it was negative in 28 (10.7%) 
patients.
In these 28 patients, the second HAV test was done 
6.5±2.3 days after the first HAV test. The interval from the 
peak-ALT day to the second test was 5.0±3.2 days (range, 
1-16 days), while the interval from the peak-BIL day to the 
second test was 1.1±3.9 days (range, -9~13 days). The 
second HAV test was done during phase II in 6 (21.4%) 
patients and during phase III in 22 (78.6%) patients (Fig. 2).
Comparison between patients with negative 
initial IgM anti-HAV and with positive initial IgM 
anti-HAV
The proportion of men was greater in the negative initial 
IgM anti-HAV group than the positive initial IgM anti-HAV 
group, while the age did not differ between the two groups 
(Table 2). Interval from day 0 to the first HAV-test day 
(3.9±2.2 days vs. 6.6±2.9 days, P<0.001) and that from 
peak-ALT day to the first HAV-test day (-1.5±1.5 days vs. 
0.7±1.6 days, P<0.001) were significantly shorter in the 
negative initial HAV test group. In all patients with negative 
initial HAV test, the test was done during phase I or II. On 
the contrary, in patients with positive initial HAV-test, the 
test was usually done during phase II or III (P<0.001). 
Serum ALT levels at the time of the initial HAV test 
showed a tendency to be lower in patients with negative 
initial HAV test (2586.8±2322.5 IU/L vs. 3033.3±1894.2 
IU/L, P=0.064), while peak-ALT levels showed a tendency 
to be higher in these patients (4016.4±2105.3 IU/L vs. 
3367.8±2016.9 IU/L, P=0.078). Serum BIL level at the time 
of the initial HAV tests was significantly lower in the 
negative initial HAV test group than the positive initial HAV 
test group (2.3±1.7 mg/dL vs. 4.8±3.2 mg/dL, P<0.001), 
while peak-BIL level did not differ between the 2 groups 
(6.5±3.4 mg/dL vs. 7.4±4.4 mg/dL, P=0.355). On multivariate 
Patients with positive
initial IgM anti-HAV
Patients with negative 
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Table 3. Subgroup analysis of patients hospitalized during phase I of AHA
Negative initial IgM 
anti-HAV (n=21)





Age (yr) 29.3±4.3 30.6±5.9 0.378
Male (n, %) 16 (84.2) 24 (57.1) 0.039 0.617
Positive hepatitis B surface antigen (n, %) 0 (0) 3 (7.1) 0.545
Duration of hospitalization (day) 9.5±2.7 11.2±7.9 0.367
Interval from the day 0 to the first HAV-test day (day) 3.1±1.1 4.5±1.6 0.001 0.518
Interval from peak-ALT day to the first HAV-test day (day) -2.3±1.1 -0.8±1.3 <0.001 0.001
Interval from peak-BIL day to the first HAV-test day (day) -6.3±2.7 -6.0±4.0 0.462
ALT level on the first HAV-test day (IU/L) 1862.4±2177.3 2345.8±1498.2 0.034 0.542
BIL level on the first HAV-test day (mg/dL) 1.7±1.1 2.0±1.1 0.262
Peak ALT level (IU/L) 3984.3±2250.1 4204.1±2158.4 0.607
Peak BIL level (mg/dL) 6.4±2.3 7.3±4.6 0.709
*Mann-Whitney  U test or chi-square test; 
†Binary logistic regression analysis.
AHA, acute hepetitis A; HAV, hepatitis A virus; ALT, alanine aminotransferase; BIL, bilirubin.
logistic regression analysis, only the duration from the peak- 
ALT day to the initial HAV-test day were significantly 
associated with negative results for the initial HAV test 
(β, -0.978; odds ratio [95% confidence interval], 0.376 
[0.189-0.747]; P=0.005). The proportion of patients with 
negative initial HAV test decreased when the initial HAV 
test time approached the peak-ALT day (likelihood ratio, 
53.8; P<0.001 on linear-by-linear association) (Fig. 3). HAV 
test was positive in all patients when it was performed at 
least 2 days after the peak-ALT day.
Subgroup analysis in patients hospitalized during 
the phase I of acute hepatitis A
The positivity of HAV tests were significantly related 
with the interval from the peak-ALT day to the HAV-test day. 
However, the peak-ALT day could not be said to have 
represented their true peak day or their true peak levels in 
patients admitted during the phase II or III. Therefore, we 
performed a subgroup analysis with patients who were 
hospitalized during the phase I.
Consistent with the results of analysis with all enrolled 
patients, proportions of men and patients who had their 
initial HAV tests during the phase I were more frequent in 
the negative initial HAV test group than in the positive initial 
HAV test group. In addition, intervals from day 0 to the 
initial HAV-test day (3.1±1.1 days vs. 4.5±1.6 days, P=0.001) 
and from peak-ALT day to the initial HAV-test day (-2.3±1.1 
days vs. -0.8±1.3 days, P<0.001) were significantly shorter 
in patients with negative initial HAV test than those with 
positive initial HAV test. Serum ALT levels at the time of the 
initial HAV test were significantly lower in patients with 
negative initial HAV test (1862.4±2177.3 IU/L vs. 2345.8± 
1498.2 IU/L, P=0.034). However, peak ALT (3984.3±2250.1 
IU/L vs. 4204.1±2158.4 IU/L, P=0.607) and BIL levels 
(6.4±2.3 mg/dL vs. 7.3±4.6 mg/dL, P=0.709) did not differ 
between 2 groups. On multivariate logistic regression 
analysis, only the interval from the peak-ALT day to the 
initial HAV-test day was significantly associated with 
the negative results for the initial HAV tests (β, -0.984; 
odds ratio [95% confidence interval], 0.374 [0.209-0.669]; 
P=0.001) (Table 3).
DISCUSSION
Our results suggest that up to 10% of patients with 
symptomatic AHA cannot be diagnosed if we rely solely on 
the result of initial HAV test. HAV RNA assay could be an 
option for diagnosing AHA in patients whose HAV test is 
negative. HAV RNA has been detected in the serum, stool, 
and liver tissue using molecular hybridization assay or 
reverse transcription-PCR assay.
10,11 However, the use of 
HAV RNA assay is still limited to research laboratories.
3 
Therefore, repeating HAV test after a certain period of time 
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seems to be more practical to make the diagnosis of AHA for 
the time being. Although repeating HAV test after 1 to 2 
weeks is generally recommended for those with initially 
negative result, not much is known about the appropriate 
time interval fit for reevaluation and studies are lacking to 
support this recommendation. The results of our study show 
that in most of the patients with negative initial HAV test, the 
test was performed before the peak-ALT day. However, 
when the initial or follow-up HAV test was performed at 
least 2 days after the peak ALT level, it was positive in all 
patients. In addition, on multivariate analysis, the only 
significant parameter associated with the result of the initial 
HAV test was the duration from peak-ALT day to the initial 
test day. Therefore, it could be suggested that the optimal 
time for repeating HAV test in clinically suspicious AHA 
patients with negative initial HAV test would be at least 2 
days after peak-ALT day.
Although previous studies have not classified and 
analyzed their data according to the clinical course of AHA 
as we have done in our study, the fact that higher proportion 
of patients presented with fever and abdominal pain
7 or 
lower ALT level and that the interval from symptom onset to 
hospital admission was shorter
12 in patients with negative 
initial HAV test suggest that, consistent with our data, initial 
tests had been performed during the phase I in the majority 
of study subjects.
When we look at Table 2, patients with negative initial 
IgM anti-HAV show lower ALT and BIL level than those 
with positive initial anti-HAV at the time of first HAV test, 
but the peak ALT and BIL level are higher in the former 
patients. Therefore, we are apt to think that these patients 
would go through a more aggressive clinical course. 
However, since most of the patients with positive initial 
HAV test have been admitted during the phase II or III, their 
true peak ALT or BIL level cannot be said to have been 
rightly assessed. To clarify whether there is any relationship 
between the result of initial HAV test and the clinical course, 
we performed a subgroup analysis only with those admitted 
during the phase I whose true peak ALT and BIL level could 
be obtained. The result of this subgroup analysis showed that 
the peak ALT and BIL level did not differ between the 
negative initial HAV test group and the positive initial HAV 
test group.
A previous study suggested that the negative results in the 
initial HAV tests are associated with the short interval from 
symptom onset to hospital admission, high body mass index, 
and low initial ALT level on the multivariate analysis.
12 
Consistently, both the duration from day 0 to the initial HAV- 
test day and the duration from peak-ALT day to the initial 
HAV-test day were associated with the results of the initial 
HAV-test day on univariate analysis in our study. However, 
only the duration from peak-ALT day to the initial HAV- 
test day was associated with the results of the initial tests 
on multivariate analysis. These results suggest that the 
appearance of IgM anti-HAV is associated with the course of 
immune response to HAV. In addition, since perception 
of AHA symptoms is very subjective, the day when 
patients first feel the symptoms may vary greatly from 
person to person during the course of the disease process. 
Furthermore, the fact that the data on first symptom 
presentation can only be obtained through history taking, 
which in turn depends entirely on the recollection by the 
patients, renders the information on first symptom presen-
tation date not so reliable. This could explain why the result 
on initial HAV test shows closer and better association with 
the duration from peak-ALT day to the initial HAV-test day, 
which is objective, than the duration from symptom onset to 
the initial HAV-test day.
Shin et al
8 suggested high initial cutoff index of HAV test 
(≥0.5), low serum BIL level (<1.4 mg/dL), and low platelet 
count (<165×10
3/µL) as predictive factors for positive result 
on HAV retesting. However, when we applied these 
suggested predictive factors to our patients, seven patients 
among 28 patients (25%) with negative initial HAV test did 
not meet any one of them.  
The result of our study shows that initial HAV tests were 
negative in 10.7% of patients with AHA, which is relatively 
higher than that of the previous studies (6.4-6.7%).
7,12 
Because these previous studies have not separately 
demonstrated the data of their patients according to the 
phase of AHA, it is difficult to clearly state the reason for 
this discrepancy on initial HAV test negativity. However, 
there is a possibility that higher proportion of patients could 
have been hospitalized during the phase I in our study. 
Because symptoms during the prodromal period, including 
fever, chill, nausea, and abdominal pain, are too nonspecific, 
it is not easy for the patient to consider themselves to have 
AHA during this period. Therefore, most of the patients with 
AHA make hospital visits during the icteric period because 
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has increased since the AHA outbreak in 2008
13 and ever 
since, more people have become more aware of AHA and 
visit the hospital to be assessed for this condition if they 
have fever of chilling sensation. Consistent with this trend, 
the proportion of patients who visited the hospital during the 
prodromal period has risen and this might have led to these 
discrepancies in our study compared to the previous studies.
In conclusion, the result of HAV test was significantly 
associated with the duration from peak-ALT day to the test 
day. The optimal time for repeating HAV test in clinically 
suspicious patients with negative initial test seems to be at 
least 2 days after peak-ALT day.
Acknowledgements
This study was supported by a grant from Ministry for 
Health and Welfare, Republic of Korea (A050021).
Conflict of interest
The authors declare no conflicts of interest.
REFERENCES
1. Kang HM, Jeong SH, Kim JW, Lee D, Choi CK, Park YS, et al. 
Recent etiology and clinical features of acute viral hepatitis in a 
single center of Korea. Korean J Hepatol 2007;13:495-502.
2. Mun JS, Kim HJ, Hue C, Kim SJ, Moon HJ, Lee HW, et al. The 
etiology of acute viral hepatitis for the last 3 years at a single 
institution in Seoul. Korean J Med 2008;74:624-631.
3. Sjogren MH, Cheatham JG. Hepatitis A. In: Feldman M, Friedman 
LS, Brandt LJ, eds. Sleisenger and Fordtran's Gastrointestinal and 
Liver Disease, 9th ed. Philadelphia PA: Saunders Elsevier, 2010: 
1279-1285.
4. Lemon SM. Type A viral hepatitis: epidemiology, diagnosis, and 
prevention. Clin Chem 1997;43:1494-1499.
5. Liaw YF, Yang CY, Chu CM, Huang MJ. Appearance and 
persistence of hepatitis A IgM antibody in acute clinical hepatitis A 
observed in an outbreak. Infection 1986;14:156-158.
6. Kao HW, Ashcavai M, Redeker AG. The persistence of hepatitis A 
IgM antibody after acute clinical hepatitis A. Hepatology 1984;4: 
933-936.
7. Lee EJ, Kwon SY, Seo TH, Yun HS, Cho HS, Kim BK, et al. Clinical 
features of acute hepatitis A in recent two years. Korean J Gastroen-
terol 2008;52:298-303.
8. Shin HP, Lee JI, Jung SW, Cha JM, Joo KR, Kang SY. Factors for 
predicting positive results for anti-HAV IgM retesting among 
initially seronegative patients. Dig Dis Sci 2010;55:3537-3540.
9. Sherlock S, Dooley J. Viral hepatitis: general features, hepatitis A, 
hepatitis E and other viruses. In: Sherlock S, Dooley J, eds. Deases 
of the Liver and Biliary System, 11th ed. Oxford: Blackwell 
Science. 2002:267-283.
10. Oren R, Shouval D, Tur-Kaspa R. Detection of hepatitis A virus 
RNA in serum from patients with acute hepatitis. J Med Virol 
1989;28:261-263.
11. Yotsuyanagi H, Iino S, Koike K, Yasuda K, Hino K, Kurokawa K. 
Duration of viremia in human hepatitis A viral infection as 
determined by polymerase chain reaction. J Med Virol 1993;40: 
35-38.
12. Jung YM, Park SJ, Kim JS, Jang JH, Lee SH, Kim JW, et al. 
Atypical manifestations of hepatitis A infection: a prospective, 
multicenter study in Korea. J Med Virol 2010;82:1318-1326.
13. Yoon YK, Chun BC, Lee HK, Seo YS, Shin JH, Hong YS, et al. 
Epidemiological and genetic analysis of a sustained community- 
wide outbreak of hepatitis A in the Republic of Korea, 2008: a 
hospital-based case-control study. J Clin Virol 2009;46:184-188.